Literature DB >> 8118804

Estradiol inhibits growth of hormone-nonresponsive PC3 human prostate cancer cells.

G Carruba1, U Pfeffer, E Fecarotta, D A Coviello, E D'Amato, M Lo Castro, G Vidali, L Castagnetta.   

Abstract

Significant inhibition of proliferative activity in PC3 human prostate cancer cells by estradiol is reported, accompanied by experimental evidence for a specific estrogen receptor (ER). Radioligand-binding assays revealed the presence of high affinity sites of estrogen binding in the nuclear compartment of PC3 cells. In addition, using a reverse transcriptase-polymerase chain reaction system, we obtained evidence of either normal or a variant ER mRNA; the latter, which lacks the entire exon 4, is coexpressed with normal ER mRNA and has been recently characterized in our laboratories. The likelihood that the inhibitory effect exerted by estradiol could be mediated by an increase of transforming growth factor beta (TGF beta) production was also investigated. Use of monoclonal antibodies against TGF beta 1 produced a 3-fold increase of growth rate in PC3 cells; this clearly speaks for high levels of endogenous TGF beta 1. This effect was almost completely abolished after addition of 100 nM estradiol. However, we failed to demonstrate any increase of TGF beta 1 mRNA after estradiol administration using Northern blot analysis. Further studies are needed to ascertain whether the estradiol-induced growth inhibition of PC3 cells is either mediated by other TGF beta species or exerted via alternative mechanism(s).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8118804

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes.

Authors:  Ilsa M Coleman; Jeffrey A Kiefer; Lisha G Brown; Tiffany E Pitts; Peter S Nelson; Kristen D Brubaker; Robert L Vessella; Eva Corey
Journal:  Neoplasia       Date:  2006-10       Impact factor: 5.715

2.  Estrogen receptor expression in prostate cancer and premalignant prostatic lesions.

Authors:  H Bonkhoff; T Fixemer; I Hunsicker; K Remberger
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

3.  Inhibition of growth and cell cycle arrest of ARCaP human prostate cancer cells by ectopic expression of ER-alpha.

Authors:  Q Ye; B Cinar; M Edlund; L W Chung; H E Zhau
Journal:  Mol Cell Biochem       Date:  2001-12       Impact factor: 3.396

4.  Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest.

Authors:  Q K Y Chan; H-M Lam; C-F Ng; A Y Y Lee; E S Y Chan; H-K Ng; S-M Ho; K-M Lau
Journal:  Cell Death Differ       Date:  2010-03-05       Impact factor: 15.828

5.  Trans-, cis-, and dihydro-resveratrol: a comparative study.

Authors:  Natalia Yu Anisimova; Mikhail V Kiselevsky; Andrey V Sosnov; Sergey V Sadovnikov; Ivan N Stankov; Andrei A Gakh
Journal:  Chem Cent J       Date:  2011-12-20       Impact factor: 4.215

6.  Aberrant DNA methylation and prostate cancer.

Authors:  Sunipa Majumdar; Eric Buckles; John Estrada; Shahriar Koochekpour
Journal:  Curr Genomics       Date:  2011-11       Impact factor: 2.236

Review 7.  Cardiac glycosides use and the risk and mortality of cancer; systematic review and meta-analysis of observational studies.

Authors:  Mohamed Hosny Osman; Eman Farrag; Mai Selim; Mohamed Samy Osman; Arwa Hasanine; Azza Selim
Journal:  PLoS One       Date:  2017-06-07       Impact factor: 3.240

Review 8.  Importance of Estrogenic Signaling and Its Mediated Receptors in Prostate Cancer.

Authors:  Kin-Mang Lau; Ka-Fai To
Journal:  Int J Mol Sci       Date:  2016-08-31       Impact factor: 5.923

9.  Induction of paclitaxel resistance by ERα mediated prohibitin mitochondrial-nuclear shuttling.

Authors:  Pei Dong; Lijuan Jiang; Jianye Liu; Zhiming Wu; Shengjie Guo; Ziling Zhang; Fangjian Zhou; Zhuowei Liu
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.